MW 401.85 g/mol, Purity >99%. Novel, multiple receptor antagonist. Displays activity at 5-HT, dopamine, adrenoceptors and histamine receptors. (pKi values are 8.60 (5-HT1A), 8.40 (5-HT1B), 10.15 (5-HT2A), 9.75 (5-HT2B), 10.46 (5-HT2C), 8.84 (5-HT5A), 9.60 (5-HT6), 9.94 (5-HT7), 8.85 (D1), 8.90 (D2L), 8.84 (D2S), 9.38 (D3), 8.95 (D4), 8.93 (α1A), 8.9 (α2A), 9.49 (α2B), 8.91 (α2C), 9.00 (H1) and 8.21(H2)). Increases dopamine, norepinephrine and acetylcholine efflux. Antipsychotic in vivo.
MW 401.85 g/mol, Purity >99%. Novel, multiple receptor antagonist. Displays activity at 5-HT, dopamine, adrenoceptors and histamine receptors. (pKi values are 8.60 (5-HT1A), 8.40 (5-HT1B), 10.15 (5-HT2A), 9.75 (5-HT2B), 10.46 (5-HT2C), 8.84 (5-HT5A), 9.60 (5-HT6), 9.94 (5-HT7), 8.85 (D1), 8.90 (D2L), 8.84 (D2S), 9.38 (D3), 8.95 (D4), 8.93 (α1A), 8.9 (α2A), 9.49 (α2B), 8.91 (α2C), 9.00 (H1) and 8.21(H2)). Increases dopamine, norepinephrine and acetylcholine efflux. Antipsychotic in vivo.
Soluble in DMSO to 100 mM.
Soluble in ethanol to 100 mM.
Novel, multiple receptor antagonist. Displays activity at 5-HT, dopamine, adrenoceptors and histamine receptors. (pKi values are 8.60 (5-HT1A), 8.40 (5-HT1B), 10.15 (5-HT2A), 9.75 (5-HT2B), 10.46 (5-HT2C), 8.84 (5-HT5A), 9.60 (5-HT6), 9.94 (5-HT7), 8.85 (D1), 8.90 (D2L), 8.84 (D2S), 9.38 (D3), 8.95 (D4), 8.93 (α1A), 8.9 (α2A), 9.49 (α2B), 8.91 (α2C), 9.00 (H1) and 8.21(H2)). Increases dopamine, norepinephrine and acetylcholine efflux. Antipsychotic in vivo.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120576, Asenapine maleate, 5-HT receptor antagonist and D2 antagonist
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com